Clinical Trials Logo

Clinical Trial Summary

The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 (rhIL-2) for MAS.


Clinical Trial Description

Autoimmune-associated macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (HLH), is a rapidly progressing life-threatening disease. VP16 (Etoposide) is a well-known standard therapy, but is associated with substantial adverse effects, especially myelosuppression and infections , while steroids and ciclosporin (CSA) are not always efficient in this disease.

The investigators hypothesized that low- dose IL-2 could be a novel therapy in MAS. This clinical study will test the efficacy and safety of low dose IL-2 treatment in MAS. The investigators perform a single-centre pilot trial with rhIL-2 in MAS. The investigators evaluate the effectiveness and safeness of low-dose IL-2 for MAS. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02569463
Study type Interventional
Source Peking University People's Hospital
Contact Jing He, MD
Phone 8618611707347
Email hejing1105@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date June 2014
Completion date June 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06405152 - Assessment of Macrophage Activation syndromE in STill's Disease
Not yet recruiting NCT03721809 - Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis N/A
Active, not recruiting NCT02780583 - Treatment of Macrophage Activation Syndrome (MAS) With Anakinra Phase 1
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Enrolling by invitation NCT01095146 - New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome N/A
Recruiting NCT06339177 - Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Not yet recruiting NCT05137496 - Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome Phase 3
Active, not recruiting NCT03827343 - Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Recruiting NCT05611710 - Anakinra in Dengue With Hyperinflammation ( AnaDen ) Phase 2
Completed NCT03311854 - A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Phase 2
Recruiting NCT05001737 - Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Phase 3
Completed NCT03332225 - A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis Phase 2
Completed NCT04339712 - Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Phase 2